10.3389/fimmu.2018.02153.s001
Anna S. Świerzko
Anna S.
Świerzko
Mateusz Michalski
Mateusz
Michalski
Anna Sokołowska
Anna
Sokołowska
Mateusz Nowicki
Mateusz
Nowicki
Łukasz Eppa
Łukasz
Eppa
Agnieszka Szala-Poździej
Agnieszka
Szala-Poździej
Iwona Mitrus
Iwona
Mitrus
Anna Szmigielska-Kapłon
Anna
Szmigielska-Kapłon
Małgorzata Sobczyk-Kruszelnicka
Małgorzata
Sobczyk-Kruszelnicka
Katarzyna Michalak
Katarzyna
Michalak
Aleksandra Gołos
Aleksandra
Gołos
Agnieszka Wierzbowska
Agnieszka
Wierzbowska
Sebastian Giebel
Sebastian
Giebel
Krzysztof Jamroziak
Krzysztof
Jamroziak
Marek L. Kowalski
Marek L.
Kowalski
Olga Brzezińska
Olga
Brzezińska
Steffen Thiel
Steffen
Thiel
Jens C. Jensenius
Jens
C. Jensenius
Katarzyna Kasperkiewicz
Katarzyna
Kasperkiewicz
Maciej Cedzyński
Maciej
Cedzyński
Data_Sheet_1_The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT).docx
Frontiers
2018
CL-LK
collectin
complement
hematopoietic stem cell transplantation (HSCT)
mannose-binding lectin (MBL)
MASP
mutliple myeloma
lymphoma
2018-09-20 04:19:21
Dataset
https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_The_Role_of_Complement_Activating_Collectins_and_Associated_Serine_Proteases_in_Patients_With_Hematological_Malignancies_Receiving_High-Dose_Chemotherapy_and_Autologous_Hematopoietic_Stem_Cell_Transplantations_Auto-HSCT_docx/7110014
<p>We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum concentrations of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were taken before conditioning chemotherapy, before HSCT and once weekly after (totally 4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation. The results were compared with data from 267 healthy controls and analyzed in relation to clinical data to explore possible associations with cancer and with chemotherapy-induced medical complications. We found a higher frequency of MBL deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients compared with controls. It was however not associated with hospital infections or post-HSCT recovery of leukocytes, but seemed to be associated with the most severe infections during follow-up. Paradoxically, high MBL serum levels were a risk factor for prolonged fever and some infections. The first possible association of MBL2 gene 3′-untranslated region polymorphism with cancer (lymphoma) in Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was relatively frequent in lymphoma patients who experienced bacteremia during hospital stay. The median concentration of CL-LK was higher in myeloma patients compared with healthy subjects. Chemotherapy induced marked increases in serum MBL and MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections following chemotherapy of myeloma and lymphoma have been reported. Here we found no evidence for an association between MBL deficiency and infection during the short period of neutropenia following conditioning treatment before HSCT. However, we noted a possible protective effect of MBL during follow-up, and suspected that to be fully effective when able to act in combination with phagocytic cells after their recovery.</p>